U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of the Commissioner
  5. Office of the Chief Scientist
  6. Office of Counterterrorism and Emerging Threats
  1. Office of the Chief Scientist

Office of Counterterrorism and Emerging Threats Also referred to as: OCET

OCET provides leadership, coordination, and oversight for FDA’s national and global health security, counterterrorism, and emerging threats portfolios.

Image
Montage of photos representing OCET activities, including scientists conducting research, professional development activities, and law books and gavel representing regulatory functions

Major Functions and Responsibilities

OCET serves as FDA’s point of entry on policy and planning matters concerning global health security, counterterrorism, and emerging threats and coordinates FDA’s Medical Countermeasures Initiative (MCMi).


The Office of Counterterrorism and Emerging Threats (OCET) provides leadership, coordination, and oversight for FDA’s national and global health security, counterterrorism, and emerging threats portfolios.

Major Functions

Serves as FDA’s point of entry on policy and planning matters concerning global health security, counterterrorism, and emerging threats

Develops and coordinates the implementation of comprehensive FDA plans and strategies for these portfolios in collaboration with FDA centers and offices, and with external U.S. government and international partners

Serves as the FDA focal point for the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) and Department of Defense medical countermeasure (MCM) programs to support the warfighter

Coordinates FDA’s Medical Countermeasures Initiative (MCMi)  to facilitate the development of safe and effective MCMs against chemical, biological, radiological, and nuclear agents and emerging threats, such as pandemic influenza

Develops and coordinates implementation of FDA policies and procedures to facilitate the availability of MCMs, including efforts to safeguard MCMs from adulteration or disruption of supplies during public health emergencies, and enable access to available MCMs when necessary through an appropriate mechanism, such as Emergency Use Authorization

On behalf of the Commissioner, facilitates communications within FDA and with external partners on counterterrorism policy, public health emergency preparedness, and global health security




Contact Us

Contact Point
Office of Counterterrorism and Emerging Threats (OCET)
Michael Mair, MPH
Acting Assistant Commissioner for Counterterrorism Policy, and Acting Director, Office of Counterterrorism and Emerging Threats
Hours Available
AskMCMi@fda.hhs.gov
301-796-8510
www.fda.gov/medicalcountermeasures
Twitter: @FDA_MCMi